Cancer  Control 2025

ONLINE EDITION

The Cancer Control Consultation

The Cancer Control Survey 2025

Cancer Control interviews Dr Miriam Mutebi, President of AORTIC

Global Issues

The 2025 UN High-level Meeting on NCDs and Mental Health: The art of negotiation
Katy Cooper, Chair, UK Working Group on NCDs; Kendra Chow, Senior Policy and Public Affairs Manager, World Cancer Research Fund International; Stephen Connor, Executive Director, Worldwide Hospice Palliative Care Alliance; Julia Downing, Chief Executive, International Children’s Palliative Care Network; George Hayes, Global Partnerships and Advocacy Manager, Cancer Research UK; Katie Jakeman, Policy Advisor, Age International; Antonis A Kousoulis, Director of Partnerships, United for Global Mental Health; and Mark Lodge, Chair, UK and Ireland Global Cancer Network

From influence to persuasion: How cancer misinformation has altered on short video platforms like TikTok
Stephanie Alice Baker, City St George’s, University of London

What can tobacco control teach us about vested interests in food and nutrition?
Suzanne Zhou, Manager – Prevention, McCabe Centre for Law and Cancer, Melbourne, Australia; Hayley Jones, Director, McCabe Centre for Law and Cancer, Melbourne, Australia; Clare Slattery, Legal Policy Advisor, McCabe Centre for Law and Cancer, Melbourne, Australia; Ma-Anne Rosales, Regional Manager – Asia, McCabe Centre for Law and Cancer, Manila, Philippines and Thomas Kehoe, Manager – Heritage Project, Cancer Council Victoria, Melbourne, Australia

CANCER AND AMR

Can the burden of antimicrobial resistance be lowered for immunocompromised cancer patients? 
A narrative review and call to action
M Bassetti, San Martino University Hospital, Genoa, Italy; A Cardone, Cancer Patients Europe, Brussels, Belgium; F Cardoso, The ABC Global Alliance, Lisbon, Portugal; V Carter, AMR Narrative, Cheshire, UK; O A Cornely, University of Cologne, Germany; M Falcone, University of Pisa, Pisa, Italy; D Gallego, European Kidney Patients’ Federation, Madrid, Spain; M Giannella and P Viale, IRCCS Policlinico S Orsola, University of Bologna, Italy; P A Grossi, Universit. degli Studi dell’Insubria, Varese, Italy; L Pagano, Catholic University of Sacred Heart, Rome, Italy; and N Silvestris, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy

The overlooked intersection: AMR’s consequences for cancer patients
Diane Flayhart, Director, Global Public Health, BD (Becton, Dickinson, and Co), Sparks, Maryland, USA

CANCER CARE

Care amidst crisis: Advancing palliative care in the WHO Eastern Mediterranean Region
Nahla Gafer, Consultant, WHO EMRO, Cairo, Egypt; Atika Al Musalami, Palliative Medicine Consultant, Royal Hospital, Muscat, Oman; Fara h Demachkieh, Head of Quality, Research and Development Unit, SANAD, Beirut, Lebanon; Sami Al Shamry, Palliative Medicine Consultant and National Palliative Care Leader, King Fahad Medical City, Riyadh, Saudi Arabia; Heba Al Sawahli, Consultant, WHO EMRO, Cairo, Egypt; Jihan, Consultant, WHO EMRO, Cairo, Egypt; Asmus Hammerich, Director, Noncommunicable Diseases and Mental Health, and Healthier Populations Department (HNM), WHO EMRO, Cairo, Egypt; and Lamia Mahmoud, Regional Adviser, WHO EMRO, Cairo, Egypt

Beyond the dispensary: Rethinking the role of pharmacists in low- and middle-income countries through co-learning, collaboration, and ethical practice
Fatima Ladha, Clinical Pharmacist and Clinical Instructor, Faculty of Pharmaceutical Sciences, University of British Columbia, Canada and Anthony Lau, Clinical Pharmacy Specialist in Emergency Medicine, Vancouver General Hospital, Canada and Clinical Assistant Professor, Faculty of Pharmaceutical Sciences, University of British Columbia, Canada

REGIONAL FOCUS

RINC: The rise and fall of a regional cooperation network for cancer control
Walter Paulo Zoss, Associate Researcher, Center for Strategic Studies, Oswaldo Cruz Institute Foundation (Fiocruz), Rio de Janeiro, Brazil; Leigh J Passman, Principal, Indicação Médica Consultoria Ltd, Rio de Janeiro, Brazil; Simon B Sutcliffe, President, Two Worlds Cancer Collaboration, Former CEO, Princess Margaret Hospital/Ontario Cancer Institute Toronto, Canada, and the BC Cancer Agency, Canada; and Luiz Antonio Santini, Associate Researcher, Center for Strategic Studies, Oswaldo Cruz Institute Foundation (Fiocruz), Rio de Janeiro, Brazil, and Former Director, National Cancer Institute (INCA), Rio de Janeiro, Brazil

Cancer prevention and control in Peru: The role of the National Institute of Neoplastic Disease (INEN)
Tatiana Vidaurre, Co-ordinator, Master’s Programme, Cayetano Heredia University, Peru; Rodrigo Motta, Medical Oncologist, National Institute of Neoplastic Diseases, Peru; Luis Andre Salinas Agramonte, Medical Oncologist, National University of San Agustín, Peru; Guillermo Valencia Mesías, Medical Oncologist, National Institute of Neoplastic Diseases, Peru; Patricia Elizabeth Rioja Viera, Medical Oncologist, National Institute of Neoplastic Diseases; Sandro Casavilca Zambrano, Director, National Tumour Bank, National Institute of National Endocrinology; Stéphane Bertani, co-Director, International Joint Laboratory of Molecular Anthropological Oncology and Oncogenic, National Tumour Bank Peru; Luis Mas, Medical Oncologist, National Institute of Neoplastic Diseases, Peru; Mónica Calderón Anticona, Clinical Oncologist Assistant, Department of Medical Oncology, National Institute of Neoplastic Diseases; Silva Neciosup Delgado, Medical Oncologist, Cayetano Heredia University, Peru; José Luis Rojas, Professor, Clinical Epidemiology Unit, Alberto Hurtado School of Medicine, Cayetano Heredia Peruvian University and Executive Director, Cancer Epidemiology and Statistics Department, National Institute of Neoplastic Diseases; Kavita Sarwal, Transformation Partner; Victor Castro, Medical Oncologist and Researcher, National University of San Marcos, Peru; and Simon B Sutcliffe, President, Two Worlds Cancer Collaboration, Canada and Editor-in Chief, Cancer Control

The realities of palliative care for cancer patients in Rwanda
Christian Ntizimira, Founder and Executive Director, African Center for Research on End-of-Life Care

The Retinoblastoma programme in Niger 2019-2029
Adam Nouhou Diori, Hôpital National Amirou Boubacar Diallo, Niamey, Niger; Yakoura Abba Kaka, Hôpital National de Niamey, Niger; Laminou Laouali, Hôpital National de Zinder; Aïchatou Mahamadou, Centre National de Lutte Contre le Cancer, Niger; Amadou Bouba Hassane Traore, Centre Hospitalier Régional de Maradi, Niger; Pierre Bey, Alliance Mondiale Contre le Cancer; Youssoufou Souley Abdoul Salam, Hôpital National Amirou Boubacar Diallo, Niamey, Niger; Amza Abdou, Hôpital National Amirou Boubacar Diallo, Niamey, Niger; Laurence Desjardins, Alliance Mondiale Contre le Cancer; and Karim Assani, Alliance Mondiale Contre le Cancer and University of Kinshasa, RD Congo

CANCER REARCH

Revisiting the hallmarks of cancer: An interconnected hierarchy as illustrated by cancer-generated lactic acid
Stephen Y C Choi, Vancouver Prostate Centre, Vancouver, British Columbia, Canada and Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, British Columbia, Canada; James Killam, Vancouver Prostate Centre, Vancouver, British Columbia, Canada and Yuzhuo Wang, Vancouver Prostate Centre, Vancouver, British Columbia, Canada, Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, British Columbia, Canada and Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada

The impact of the SIOP Programme for advancing research capacity on global childhood cancer research
Guillermo Chantada, Head, Outreach Program, Pediatric Cancer Center Barcelona-PCCB, Hospital Sant Joan de Déu, Barcelona, Spain and Scientific Director, Fundación Pérez Scremini, Montevideo, Uruguay; Milena Villarroel, Pediatric Hemato-Oncologist, Hospital Luis Calvo Mackenna, Santiago, Chile; Trijn Israels, Paediatric Oncologist and Project Leader, Zero Abandonment from Start to Finish, CANCaRe Africa; Ramandeep Singh Arora, Visiting Consultant and Associate Director of Paediatric Oncology, Max Super Speciality Hospital, New Delhi, India; Tzvetomira Laub, Executive Director for Programmes and Strategy, International Society of Paediatric Oncology (SIOP); Carl E Allen, Professor of Pediatrics, Baylor College of Medicine and Milton and Allene Nirken Chair in Pediatric Oncology, Texas Children’s Hospital, Houston, USA and Kathy Pritchard-Jones, Emeritus Professor of Paediatric Oncology, UCL Great Ormond Street Institute of Child Health, University College London, London, UK